Aggressive variants of castration-resistant prostate cancer - Wikidata - awgldk - TriplyDB

Aggressive variants of castration-resistant prostate cancer

Aggressive variants of castration-resistant prostate cancer

http://www.wikidata.org/entity/Q33693256

about

Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention Galeterone for the treatment of advanced prostate cancer: the evidence to date Technical challenges in the isolation and analysis of circulating tumor cells Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer The many ways to make a luminal cell and a prostate cancer cell Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.Molecular pathways and targets in prostate cancer A systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes.Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.De novo large cell neuroendocrine carcinoma of the prostate, case report and literature review The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.Polycomb-mediated silencing in neuroendocrine prostate cancer.Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Integrative molecular profiling of routine clinical prostate cancer specimens.Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.Extracellular pH Modulates Neuroendocrine Prostate Cancer Cell Metabolism and Susceptibility to the Mitochondrial Inhibitor Niclosamide.Up-Regulated Expression of LAMP2 and Autophagy Activity during Neuroendocrine Differentiation of Prostate Cancer LNCaP Cells Advanced neuroendocrine prostate tumors regress to stemness Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer.Isolation and analysis of discreet human prostate cellular populations GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.Therapeutic Approaches Targeting MYC-Driven Prostate Cancer Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.Neuroendocrine differentiation of prostate cancer: a review.Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.Molecular biomarkers to guide precision medicine in localized prostate cancer.A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector.Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells.Characterization of fibroblast-free CWR-R1ca castration-recurrent prostate cancer cell line.

P2860

Q21129293-741C4305-2141-4672-A6DE-49A9456B9D48 Q26739887-7FE8A8BB-FB80-4F9B-81D4-B272F8B00864 Q26741646-4D6D620D-F0C2-4206-A34D-CBA8F24D50AD Q26773634-B7091097-73DB-459C-82E6-BB91C6C4ED18 Q26797386-8594BBA5-4443-4DB1-9E47-B0A9F0904D94 Q27334558-A71B9187-78E6-4240-A04B-682F4C8F1DA3 Q28067556-3E78FD26-E55C-450E-B2AC-48DA93B52AAE Q28075965-86662896-24CD-4D94-8774-4DE4F65EC2CF Q30277291-412B1C2E-2B2E-4F56-90E7-6808807B1616 Q33701534-1F98B615-3446-4CA0-B8DC-A37A72CAB80D Q34365632-9A45501E-4F1F-41F6-99FE-84F0F73E8FEC Q34549577-15429566-5FF0-47AD-BA96-598AEBBCD6E2 Q34550412-5044D624-9080-4157-8B98-4A2FBE229426 Q34978736-BB4B74B4-2B1D-42CA-B70E-5C80B961D168 Q35224818-27DF6C86-BDFB-4318-AA81-13810747AB90 Q35336915-B8E19830-481F-4207-A2B5-ADEA8C6B4A8A Q35555483-09C67682-B51E-4BD4-9294-C4072FFD5008 Q35833703-47E6770A-1120-4920-8548-CF46DBB85FA1 Q35879087-63077BB7-D250-40B0-9B9A-596E8CCF35E8 Q35892022-06EBD8A1-B586-45C8-B1E0-E4C781C04869 Q35925835-24C04604-966C-4104-B952-E8770830E88A Q35980945-66C380F2-67A0-4519-84BA-ED0ACBD5BE03 Q36030759-731694D9-FF59-464E-9A4A-1D98C587DDF3 Q36083012-660BBF59-0955-4907-B4DE-F78E00F74D97 Q36132777-4B4024FF-EADA-4830-BBC5-D43AC6640EA0 Q36332128-130A5B23-051C-403E-97F3-F7CE22ED8AF0 Q36637412-CE8F8C3C-C6C1-404C-B100-A55A2764CC3A Q36863464-35F1CD69-1242-4F33-943E-5EA24A6BDD3D Q37564369-D8993FE0-E854-497B-82AF-D2DEED902B5E Q37641718-386585AE-29E7-4CE3-8AF2-4929F9F582BD Q37676253-57CC6732-E27B-48DE-8BC8-B8BB17CFB72B Q37709535-F4EAC303-8568-4371-96EB-2E9E8E0666F6 Q38326554-A2180674-68D8-4389-BDA5-49C06133C0CC Q38362686-E8423EC5-A847-4AC3-A5A0-C2BF585BD2F4 Q38374417-D9FD4EB0-445E-49E5-9155-5E8BAAB94609 Q38668635-65487397-F9A8-4386-9D5D-BC86AF41966F Q38720538-F2953BDE-680D-4F4E-BA00-612FD02AB5F1 Q38722705-1BA11150-6F34-437F-8898-4D5DC1363950 Q38763212-FE593AC6-C68B-4209-8DA4-795EF6057AA4 Q38766081-A837C086-E0AA-45E4-A2BB-5F74108285C6

P2860

Aggressive variants of castration-resistant prostate cancer

http://www.wikidata.org/entity/Q33693256

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Aggressive variants of castration-resistant prostate cancer

@ast

Aggressive variants of castration-resistant prostate cancer

@en

type

label

Aggressive variants of castration-resistant prostate cancer

@ast

Aggressive variants of castration-resistant prostate cancer

@en

prefLabel

Aggressive variants of castration-resistant prostate cancer

@ast

Aggressive variants of castration-resistant prostate cancer

@en

P1433

Q33693256-95D06C4E-5007-46C6-B13C-29730802A3FB

P1476

Q33693256-656AB416-300D-409F-8E2B-C3B868AB258F

P2093

Q33693256-0BE46AF2-FC00-4579-B2FB-DD5CBD9551E1

Q33693256-1A230063-44FC-4A91-902E-C77477190C43

Q33693256-3FA7ABCD-4A3B-4095-A7E6-4CABD14E8AF0

Q33693256-608E9EAF-676C-41C9-AABD-CA48ED6E9D5F

Q33693256-6D57D241-165A-4C9C-A6AE-09840879C29E

Q33693256-6E097256-E874-4D16-B1A1-163FC5BAAF10

Q33693256-7AC596C0-80A1-4D2F-AB70-C7CD1E91035E

Q33693256-8D9B2A55-9408-4632-B79F-77CA9B87C8F0

Q33693256-E0A62C3D-FDA3-493E-8061-730B1447C8A2

Q33693256-F0B996E9-AB37-4ABC-A8CE-2F8AA1B8D7C7

P2860

Q33693256-00B14484-46DC-4775-81B5-A8E8A4960EFC

Q33693256-02CDE95E-38D6-4F8A-B941-7108620FEDFC

Q33693256-0655386A-9BA9-4706-9129-1C6A72BA3752

Q33693256-0CF96013-15C0-4090-A0CC-3AD315CEE30B

Q33693256-17A2157F-4269-46F1-8D4F-1DF3748579A4

Q33693256-40F0991E-4A2B-4DAE-9EFB-E245AD93A1DE

Q33693256-4C8C173F-1FD1-4EAA-A957-C408E7D44D71

Q33693256-728CF1B7-316B-4A02-8D14-6AB8913A7799

Q33693256-866F834B-AE02-446E-8C54-83EF65641E69

Q33693256-8B7B9B3C-D76B-45AD-BD12-1097E4FA7CE0

P304

Q33693256-A94FEFAA-A048-4BBD-9BC5-3EF8AD2D0507

P31

Q33693256-7D040828-42E8-4712-BD9E-65A3EA98357A

P356

Q33693256-6B08E6D9-566A-4647-995D-82A43539AC39

P407

Q33693256-79806D24-7783-4152-8E98-C8128A79A48B

P433

Q33693256-19F6527F-656C-4540-BF40-578A91308506

P478

Q33693256-C40DCED9-1567-4356-8188-41FFA01263E3

P50

Q33693256-1BDB7638-F94F-479B-9E8C-E27AF97EF838

P577

Q33693256-7A567777-E692-46FB-A2B3-4ED34B51A956

P698

Q33693256-E10D6DEC-1886-41C1-B502-3CAE5042E899

P932

Q33693256-75FCD120-ED8F-4CE3-8B72-8D0301B75ED3

P356

1078-0432.CCR-13-3309

P1433

Clinical Cancer Research

P1476

Aggressive variants of castration-resistant prostate cancer

@en

P2093

Ana Aparicio

http://www.w3.org/2001/XMLSchema#string

Christopher Logothetis

http://www.w3.org/2001/XMLSchema#string

David Rickman

http://www.w3.org/2001/XMLSchema#string

Gustavo Ayala

http://www.w3.org/2001/XMLSchema#string

Himisha Beltran

http://www.w3.org/2001/XMLSchema#string

Howard Soule

http://www.w3.org/2001/XMLSchema#string

Jiaoti Huang

http://www.w3.org/2001/XMLSchema#string

Lawrence True

http://www.w3.org/2001/XMLSchema#string

Martin E Gleave

http://www.w3.org/2001/XMLSchema#string

Scott Tomlins

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

The polycomb group protein EZH2 is involved in progression of prostate cancer

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance

Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.

Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.

Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.

Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer.

Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.

Platinum-based chemotherapy for variant castrate-resistant prostate cancer.

P304

2846-2850

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-3309

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24727321

http://www.w3.org/2001/XMLSchema#string

P932

4040316

http://www.w3.org/2001/XMLSchema#string